Precision Optics Corporation, Inc. — Form 10-Q Summary
Business context and reporting period. The company develops and manufactures precision optical instruments, components, and medical imaging systems, serving medical-device, defense/aerospace, and industrial markets. This unaudited report covers the quarter and six months ended December 31, 2023, the second quarter and first half of fiscal 2024, compared with the same periods in fiscal 2023.
Financial performance and position
| Metric | Three months ended Dec. 31, 2023 | Six months ended Dec. 31, 2023 |
|---|---|---|
| Revenue | $4.82 million | $9.15 million |
| Gross profit / margin | $1.45 million / 30.1% | $2.91 million / 31.9% |
| Operating income (loss) | $(704,162) | $(1.11) million |
| Net income (loss) | $(758,802) | $(1.22) million |
| Basic and diluted loss per share | $(0.13) | $(0.20) |
- Cash flow: First-half operating cash use was $1.49 million; investing cash use was $171,000 and financing cash use was $275,000. Cash fell $1.94 million to $987,000 from $2.93 million at June 30, 2023.
- Liquidity: At December 31, current assets were $7.83 million and current liabilities were $4.31 million. The $1.25 million revolving credit facility was undrawn and fully available, subject to its borrowing base.
- Debt: Long-term debt principal was $2.47 million, including $513,000 of current maturities; the balance sheet also reports capital lease obligations of $90,000. Term loans are secured by company assets and include a 1.20:1 annual debt-service coverage covenant based on EBITDA plus stock-based compensation.
- Other balance-sheet items: Inventory was $3.10 million, up from $2.78 million at June 30; stockholders’ equity was $11.32 million. The company had approximately 6.07 million shares outstanding at December 31.
Material changes versus prior comparable periods
- Quarterly revenue decreased 18.1% year over year; first-half revenue decreased 16.6%. The prior-year periods included $600,000 of one-time technology-rights revenue, with no associated cost of sales.
- Engineering design revenue rose 33.1% in the quarter and 24.6% for the first half, which management attributed to stronger service demand and expanded engineering capacity. Management said these engagements may transition into manufacturing orders.
- Optical components revenue fell 23.3% in the quarter and 25.8% for the first half. Management cited weaker industry demand and customer inventory rebalancing after elevated ordering linked to supply-chain concerns.
- Finished products and assemblies revenue declined 42.4% in the quarter and 38.9% for the first half, reflecting timing between mature program exits, reorders, and new programs.
- Gross margin fell to 30.1% from 44.2% for the quarter and to 31.9% from 38.6% for the first half. Excluding the prior-year technology-rights revenue, prior-year margins would have been 37.8% and 35.1%, respectively. The company also recorded a $75,000 increase in its excess and obsolete inventory reserve.
- The company moved from prior-year profit to losses in both the quarter and first half. First-half R&D expense increased 18.7% to $434,000 and SG&A increased 5.5% to $3.59 million. Management cited product-development staffing, personnel and travel costs, stock-based compensation, and higher doubtful-account reserves.
Outlook, commentary, risks, and unusual items
- No quantified revenue, earnings, or cash-flow guidance is provided. Management expects its customer project pipeline to expand and anticipates that some engineering projects will progress to production; timing and conversion are uncertain.
- Management is pursuing product development in areas including microprecision optics, micro medical cameras, illumination, single-use endoscopes, and 3D endoscopes. It describes the single-use endoscope segment as growing faster than the overall minimally invasive surgery market; this is management’s estimate, not a reported company forecast.
- Management identified competitive pressure, including larger competitors, and exposure to customer demand, inventory cycles, and the timing of program transitions. It cautioned that actual results may differ materially from forward-looking statements.
- Cash consumption, working-capital needs, debt service, and covenant requirements warrant attention. Open purchase-order commitments were approximately $3.16 million at December 31, 2023. The filing reports no outstanding revolver borrowings.
- Stock-based compensation was $491,000 for the first half. Approximately 1.26 million options were excluded from diluted share calculations because they were antidilutive during the loss periods. A full valuation allowance was maintained against deferred tax assets; management reported no estimated goodwill or patent impairment.
- Management reported disclosure controls and internal control over financial reporting were effective at December 31, 2023, with no material change in internal control during the period. It reported no pending or threatened litigation known to have a material impact.
Key facts for investors to verify
- Whether the $987,000 cash balance and $1.25 million undrawn revolver provide adequate liquidity if operating cash use continues.
- Whether management meets the loan covenant and how debt payments affect cash, particularly given the first-half operating loss and scheduled principal repayments.
- Whether engineering engagements convert into production revenue, and whether optical-component and finished-product demand recovers as customers complete inventory rebalancing and new programs ramp.
- How margins evolve after the prior-year one-time technology-rights revenue and the current-period inventory reserve increase.
- The level and collection risk of receivables, the adequacy of the doubtful-account and inventory reserves, and the timing of the approximately $3.16 million in open purchase-order commitments.
- The potential dilution from outstanding options and the sustainability of spending, including stock-based compensation, relative to available cash.